Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.23
RMD's Cash to Debt is ranked higher than
71% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. RMD: 2.23 )
RMD' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 2.23

Equity to Asset 0.70
RMD's Equity to Asset is ranked higher than
78% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. RMD: 0.70 )
RMD' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.86
Current: 0.7

0.34
0.86
Interest Coverage 55.55
RMD's Interest Coverage is ranked higher than
78% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. RMD: 55.55 )
RMD' s 10-Year Interest Coverage Range
Min: 26.38   Max: 9999.99
Current: 55.55

26.38
9999.99
F-Score: 6
Z-Score: 8.25
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 23.43
RMD's Operating margin (%) is ranked higher than
93% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. RMD: 23.43 )
RMD' s 10-Year Operating margin (%) Range
Min: -25.07   Max: 28.66
Current: 23.43

-25.07
28.66
Net-margin (%) 20.28
RMD's Net-margin (%) is ranked higher than
93% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. RMD: 20.28 )
RMD' s 10-Year Net-margin (%) Range
Min: 7.5   Max: 20.28
Current: 20.28

7.5
20.28
ROE (%) 19.07
RMD's ROE (%) is ranked higher than
93% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. RMD: 19.07 )
RMD' s 10-Year ROE (%) Range
Min: 7.12   Max: 23.65
Current: 19.07

7.12
23.65
ROA (%) 13.89
RMD's ROA (%) is ranked higher than
94% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. RMD: 13.89 )
RMD' s 10-Year ROA (%) Range
Min: 4.04   Max: 19.23
Current: 13.89

4.04
19.23
ROC (Joel Greenblatt) (%) 49.96
RMD's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. RMD: 49.96 )
RMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39.02   Max: 60.49
Current: 49.96

-39.02
60.49
Revenue Growth (%) 13.70
RMD's Revenue Growth (%) is ranked higher than
87% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. RMD: 13.70 )
RMD' s 10-Year Revenue Growth (%) Range
Min: -19.3   Max: 86.6
Current: 13.7

-19.3
86.6
EBITDA Growth (%) 18.10
RMD's EBITDA Growth (%) is ranked higher than
90% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. RMD: 18.10 )
RMD' s 10-Year EBITDA Growth (%) Range
Min: -27.2   Max: 141
Current: 18.1

-27.2
141
EPS Growth (%) 19.50
RMD's EPS Growth (%) is ranked higher than
86% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. RMD: 19.50 )
RMD' s 10-Year EPS Growth (%) Range
Min: -36.4   Max: 106.1
Current: 19.5

-36.4
106.1
» RMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

RMD Guru Trades in Q1 2013

Chuck Royce 31,900 sh (+1126.92%)
John Hussman 500,000 sh (+66.67%)
Paul Tudor Jones 17,900 sh (+65.74%)
Jeremy Grantham 68,289 sh (+6.53%)
Jean-Marie Eveillard 22,000 sh (unchged)
Larry Robbins 110,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Joel Greenblatt 22,566 sh (-39.33%)
» More
Q2 2013

RMD Guru Trades in Q2 2013

Steven Cohen 56,118 sh (New)
Joel Greenblatt 56,317 sh (+149.57%)
Chuck Royce 47,600 sh (+49.22%)
Jean-Marie Eveillard 22,000 sh (unchged)
Jeremy Grantham 62,342 sh (-8.71%)
John Hussman 350,000 sh (-30%)
Paul Tudor Jones 8,000 sh (-55.31%)
» More
Q3 2013

RMD Guru Trades in Q3 2013

Jim Simons 692,100 sh (New)
Jeremy Grantham 86,800 sh (+39.23%)
Jean-Marie Eveillard 22,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 46,400 sh (-2.52%)
John Hussman 315,000 sh (-10%)
Joel Greenblatt 25,192 sh (-55.27%)
Steven Cohen 9,804 sh (-82.53%)
» More
Q4 2013

RMD Guru Trades in Q4 2013

Paul Tudor Jones 17,019 sh (New)
Chase Coleman 1,000,000 sh (New)
Joel Greenblatt 234,887 sh (+832.39%)
Steven Cohen 15,093 sh (+53.95%)
Chuck Royce 46,800 sh (+0.86%)
Jean-Marie Eveillard 22,000 sh (unchged)
Jeremy Grantham 86,471 sh (-0.38%)
Jim Simons 619,800 sh (-10.45%)
John Hussman 235,000 sh (-25.4%)
» More
» Details

Insider Trades

Latest Guru Trades with RMD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Add 832.39%0.23%$45.36 - $57.11 $ 47.44-6%234887
John Hussman 2013-12-31 Reduce -25.4%0.23%$45.36 - $57.11 $ 47.44-6%235000
Joel Greenblatt 2013-09-30 Reduce -55.27%0.06%$43.26 - $54.36 $ 47.44-2%25192
John Hussman 2013-06-30 Reduce -30%0.26%$44.02 - $51.17 $ 47.440%350000
Joel Greenblatt 2013-06-30 Add 149.57%0.07%$44.02 - $51.17 $ 47.440%56317
John Hussman 2013-03-31 Add 66.67%0.34%$41.57 - $48.37 $ 47.448%500000
Joel Greenblatt 2013-03-31 Reduce -39.33%0.04%$41.57 - $48.37 $ 47.448%22566
John Hussman 2012-12-31 New Buy0.33%$38.82 - $42.77 $ 47.4416%300000
Joel Greenblatt 2012-12-31 Add 63.18%0.03%$38.82 - $42.77 $ 47.4416%37193
Joel Greenblatt 2012-09-30 Reduce -60.79%0.08%$30.63 - $40.47 $ 47.4435%22793
John Hussman 2012-06-30 Sold Out 0.21%$30.12 - $34.64 $ 47.4449%0
Joel Greenblatt 2012-06-30 Add 165.27%0.08%$30.12 - $34.64 $ 47.4449%58134
John Hussman 2012-03-31 Reduce -26.62%0.05%$24.81 - $31.99 $ 47.4474%350000
Joel Greenblatt 2011-12-31 New Buy0.07%$23.46 - $31.7 $ 47.4474%21376
Jean-Marie Eveillard 2011-12-31 Add 120%$23.46 - $31.7 $ 47.4474%22000
Jean-Marie Eveillard 2011-09-30 Add 25%$25.76 - $33.17 $ 47.4459%10000
Jean-Marie Eveillard 2011-06-30 New Buy$29.62 - $33.92 $ 47.4450%8000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.00
RMD's P/E(ttm) is ranked higher than
77% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.10 vs. RMD: 21.00 )
RMD' s 10-Year P/E(ttm) Range
Min: 16.9   Max: 66.2
Current: 21

16.9
66.2
P/B 3.90
RMD's P/B is ranked lower than
51% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. RMD: 3.90 )
RMD' s 10-Year P/B Range
Min: 2.29   Max: 5.94
Current: 3.9

2.29
5.94
P/S 4.40
RMD's P/S is ranked lower than
64% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. RMD: 4.40 )
RMD' s 10-Year P/S Range
Min: 2.78   Max: 6.93
Current: 4.4

2.78
6.93
PFCF 21.10
RMD's PFCF is ranked higher than
78% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. RMD: 21.10 )
RMD' s 10-Year PFCF Range
Min: 13.43   Max: 284.56
Current: 21.1

13.43
284.56
EV-to-EBIT 16.10
RMD's EV-to-EBIT is ranked higher than
74% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. RMD: 16.10 )
RMD' s 10-Year EV-to-EBIT Range
Min: 12.4   Max: 48.5
Current: 16.1

12.4
48.5
PEG 1.00
RMD's PEG is ranked higher than
89% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.13 vs. RMD: 1.00 )
RMD' s 10-Year PEG Range
Min: 0.64   Max: 5.64
Current: 1

0.64
5.64
Shiller P/E 30.10
RMD's Shiller P/E is ranked higher than
57% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. RMD: 30.10 )
RMD' s 10-Year Shiller P/E Range
Min: 24.48   Max: 67.17
Current: 30.1

24.48
67.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
RMD's Dividend Yield is ranked higher than
91% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. RMD: 2.00 )
RMD' s 10-Year Dividend Yield Range
Min: 0.41   Max: 1.94
Current: 2

0.41
1.94
Dividend Payout 0.38
RMD's Dividend Payout is ranked higher than
69% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.33 vs. RMD: 0.38 )
RMD' s 10-Year Dividend Payout Range
Min: 0.29   Max: 0.45
Current: 0.38

0.29
0.45
Yield on cost (5-Year) 2.00
RMD's Yield on cost (5-Year) is ranked higher than
86% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. RMD: 2.00 )
RMD' s 10-Year Yield on cost (5-Year) Range
Min: 0.41   Max: 1.94
Current: 2

0.41
1.94
Share Buyback Rate 1.90
RMD's Share Buyback Rate is ranked higher than
92% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. RMD: 1.90 )
RMD' s 10-Year Share Buyback Rate Range
Min: 24.5   Max: -64.5
Current: 1.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.90
RMD's Price/Net Cash is ranked lower than
56% of the 68 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.30 vs. RMD: 24.90 )
RMD' s 10-Year Price/Net Cash Range
Min: 11.81   Max: 301.29
Current: 24.9

11.81
301.29
Price/Net Current Asset Value 11.30
RMD's Price/Net Current Asset Value is ranked higher than
59% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. RMD: 11.30 )
RMD' s 10-Year Price/Net Current Asset Value Range
Min: 6.61   Max: 96.27
Current: 11.3

6.61
96.27
Price/Tangible Book 5.10
RMD's Price/Tangible Book is ranked higher than
54% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. RMD: 5.10 )
RMD' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 35.03
Current: 5.1

1.5
35.03
Price/DCF (Projected) 1.50
RMD's Price/DCF (Projected) is ranked higher than
61% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. RMD: 1.50 )
RMD' s 10-Year Price/DCF (Projected) Range
Min: 1.34   Max: 22.58
Current: 1.5

1.34
22.58
Price/Median PS Value 1.00
RMD's Price/Median PS Value is ranked higher than
70% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. RMD: 1.00 )
RMD' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 2.56
Current: 1

0.34
2.56
Price/Peter Lynch Fair Value 1.10
RMD's Price/Peter Lynch Fair Value is ranked higher than
97% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. RMD: 1.10 )
RMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7   Max: 11.67
Current: 1.1

0.7
11.67
Price/Graham Number 2.10
RMD's Price/Graham Number is ranked higher than
65% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. RMD: 2.10 )
RMD' s 10-Year Price/Graham Number Range
Min: 1.01   Max: 14.66
Current: 2.1

1.01
14.66
Earnings Yield (Greenblatt) 6.20
RMD's Earnings Yield (Greenblatt) is ranked higher than
74% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. RMD: 6.20 )
RMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.1
Current: 6.2

2.1
8.1
Forward Rate of Return (Yacktman) 21.82
RMD's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. RMD: 21.82 )
RMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.1   Max: 31.1
Current: 21.82

9.1
31.1

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RMD.Australia, RME.Germany, RMEA.Germany, RSMDF.USA
ResMed Inc. a Delaware corporation was formed in March 1994. The Company is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing, or SDB, includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. When it was formed in 1989, its primary purpose was to commercialize a treatment for OSA developed by Professor Colin Sullivan. This treatment, nasal Continuous Positive Airway Pressure, or CPAP, was the first successful noninvasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, it has developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. The Company's portfolio of products for the treatment of OSA and other forms of SDB includes airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces CPAP, VPAP and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Mask systems are one of the most important elements of SDB treatment systems. Masks are a primary determinant of patient comfort and as such might drive or impede patient compliance with therapy. It currently markets its products using a network of distributors, independent manufacturers' representatives and its direct sales force. The markets for its products are highly competitive. In the United States, its main market, Philips BV, who acquired Respironics Inc., a previous competitor; DeVilbiss, a division of Sunrise Medical Inc.; Nellcor Puritan Bennett, a division of Covidien Ltd.; and Fisher & Paykel Healthcare Corporation Limited are the primary competitors for its products. The Company's main European competitors are also Philips, DeVilbiss, and Nellcor Puritan Bennett, as well as regional European manufacturers. The Company's products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide